Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and thirteen have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $38.7857.

Several research analysts have commented on VRDN shares. The Goldman Sachs Group reissued a “buy” rating and set a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Weiss Ratings cut Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. Evercore set a $26.00 price target on Viridian Therapeutics in a research note on Friday, May 15th. Finally, HC Wainwright cut their price target on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, March 31st.

Insider Activity at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in Viridian Therapeutics during the first quarter valued at $34,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics in the 4th quarter worth $36,000. Larson Financial Group LLC purchased a new position in shares of Viridian Therapeutics in the 3rd quarter worth $52,000. US Bancorp DE increased its holdings in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Viridian Therapeutics in the 1st quarter worth about $93,000.

Viridian Therapeutics Trading Down 5.4%

Viridian Therapeutics stock opened at $18.03 on Friday. Viridian Therapeutics has a 1 year low of $13.18 and a 1 year high of $34.29. The firm’s 50 day moving average price is $17.47 and its 200-day moving average price is $22.91. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The stock has a market cap of $1.86 billion, a P/E ratio of -5.43 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. Viridian Therapeutics’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.87) earnings per share. On average, equities analysts predict that Viridian Therapeutics will post -3.87 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.